IQVIA Holdings Inc. (NYSE:IQV) Receives $255.82 Consensus PT from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has earned a consensus recommendation of “Moderate Buy” from the twenty-one analysts that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $255.82.

Several equities research analysts recently weighed in on IQV shares. Truist Financial decreased their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price for the company. Bank of America cut their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st.

IQVIA Stock Up 1.2 %

Shares of NYSE IQV opened at $197.39 on Wednesday. The business has a 50-day moving average of $202.86 and a two-hundred day moving average of $222.01. The company has a market capitalization of $35.83 billion, a price-to-earnings ratio of 25.90, a price-to-earnings-growth ratio of 2.05 and a beta of 1.49. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Institutional Trading of IQVIA

A number of institutional investors have recently modified their holdings of the business. First Foundation Advisors lifted its holdings in IQVIA by 3.8% in the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares during the period. Invera Wealth Advisors LLC boosted its holdings in IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after buying an additional 46 shares in the last quarter. Private Trust Co. NA grew its position in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after buying an additional 47 shares during the period. Oregon Public Employees Retirement Fund lifted its position in shares of IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after acquiring an additional 48 shares during the period. Finally, Clear Harbor Asset Management LLC boosted its stake in shares of IQVIA by 1.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after acquiring an additional 50 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.